References by Topic

Click on the following subheadings to go to some of the important references relevant to that topic. Clicking on the reference will take you to a set of slides summarizing the material presented in the reference.

ADJUVANT THERAPY

Mitry E et al. Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials. J Clin Oncol 2008;26:4906-11.

Vauthey, JN, Pawlik, TM, Ribero, D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.

BEVACIZUMAB AND CETUXIMAB

Bokemeyer C et al. Cetuximab Plus 5-FU/FA/Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC): OPUS, a Randomized Phase II Study. Proc ASCO 2007 [Abstract 4035]

Bokemeyer C et al. K-ras Status and Efficacy of First-Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) with FOLFOX with or without Cetuximab: The OPUS Experience ASCO 2008 [A4000]

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.  Lancet Oncol. 2010 Jan;11(1):38-47. Epub 2009 Nov 26.

Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008 Apr 10;26(11):1830-5.

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008 Nov 10;26(32):5254-60.

Klinger, M, Kandutsch, S, Hacker, S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: Effect of bevacizumab (abstract). Proc ASCO 2008 [abstract 4082]

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009 May;35(5):515-20.

Moosmann N, Heinemann V. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2008 Mar;8(3):319-29. 

Moosmann N, Heinemann V. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Mar;7(2):110-7

Saltz, LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.

Reddy SK, Morse, MA Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96.

Sugrue, MM, Purdie, DM, Feng, S, et al. Serious would healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: Results form the BRiTE observational cohort study. Proc ASCO 2008;Abstract 4026.

Van Cutsem E et al. Cetuximab Added to FOLFIRI Significantly Improves Progression-Free Survival in Patients with Previously Untreated Metastatic Colorectal Cancer (CRYSTAL Study). Proc ASCO 2007 [A4000]

Van Cutsem E et al. KRAS Status and Efficacy in the First-Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI  with or without Cetuximab: The CRYSTAL Experience. Proc ASCO 2008 [A2]

Wicherts DA, de Haas RJ, Sebagh M, Saenz Corrales E, Gorden DL, Lévi F, Paule B, Azoulay D, Castaing D, Adam R. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.  Br J Surg. 2011 Mar;98(3):399-407. doi: 10.1002/bjs.7368. Epub 2010 Dec 15.

CHEMOTHERAPY FOR COLON CANCER

Bokemeyer C et al. Cetuximab Plus 5-FU/FA/Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC): OPUS, a Randomized Phase II Study. Proc ASCO 2007 [Abstract 4035]

Bokemeyer C et al. K-ras Status and Efficacy of First-Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) with FOLFOX with or without Cetuximab: The OPUS Experience ASCO 2008 [A4000]

Moosmann N, Heinemann V. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2008 Mar;8(3):319-29. 

Moosmann N, Heinemann V. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Mar;7(2):110-7

Saltz, LB, Clarke, S, Diaz-Rubio, E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.

Van Cutsem E et al. Cetuximab Added to FOLFIRI Significantly Improves Progression-Free Survival in Patients with Previously Untreated Metastatic Colorectal Cancer (CRYSTAL Study). Proc ASCO 2007 [A4000]

Van Cutsem E et al. KRAS Status and Efficacy in the First-Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI  with or without Cetuximab: The CRYSTAL Experience. Proc ASCO 2008 [A2]

CHEMOTHERAPY-ASSOCIATED TOXICITY

Fernandez, FG, Ritter, J, Goodwin, JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200:845.

Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. 2008 Nov;34(11):1231-6.

Klinger, M, Kandutsch, S, Hacker, S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: Effect of bevacizumab (abstract). Proc ASCO 2008 [4082]

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009 May;35(5):515-20.

Ribero, D, Wang, H, Donadon, M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761.

Vauthey, JN, Pawlik, TM, Ribero, D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.

EXTRAHEPATIC DISEASE RESECTION

Lee WS, Yun HR, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Park YS, Kang WK. Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e367-72.

Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007 Aug;205(2):231-8.

Mineo TC, Ambrogi V, Tonini G, Bollero P, Roselli M, Mineo D, Nofroni I. Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg. 2003 Sep;197(3):386-91.

Pulitanò C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, Parks RW, Choti MA, Wigmore SJ, Gruenberger T, Pawlik TM. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011 May;18(5):1380-8. Epub 2010 Dec 7.

Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006 Mar;202(3):468-75.

GENERAL REVIEW

Leonard, GD, Brenner, B, Kemeny, NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23:2038.

Nesbitt C, Glendinning RJ, Byrne C, Poston GJ. Factors that influence treatment strategies in advanced colorectal cancer.  Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S88-94. Epub 2007 Nov 26. Review.

van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010 Nov;14(11):1691-700. Epub 2010 Sep 14.

METACHRONOUS COLORECTAL LIVER METASTASES

Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007 Aug;205(2):231-8.

PATIENT SUBSETS

Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, Poston GJ, Wicherts DA, de Haas RJ; Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010 Mar;97(3):366-76.

de Liguori Carino N, van Leeuwen BL, Ghaneh P, Wu A, Audisio RA, Poston GJ. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol. 2008 Sep;67(3):273-8.

Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases.  Gut. 2006 Aug;55 Suppl 3:iii1-8. No abstract available.

Tamandl D, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol. 2009 Feb 20. [Epub ahead of print]

PERI-OPERATIVE OR POST-OPERATIVE SYSTEMIC THERAPY

Abdalla EK, Ribero D, Pawlik TM, Zorzi D, Curley SA, Muratore A, Andres A, Mentha G, Capussotti L, Vauthey JN. Resection of hepatic colorectal metastases involving the caudate lobe: perioperative outcome and survival. J Gastrointest Surg. 2007 Jan;11(1):66-72.

D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759.

Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039.

Kemeny MM, Adak S, Gray, B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20:1499.

Nordlinger B et al. Perioperative Chemotherapy with FOLFOX4 and Surgery versus Surgery Alone for Resectable Liver Metastases from Colorectal Cancer (EORTC Intergroup Trial 40983): A Randomised Controlled Trial. Lancet 2008;371:1007-16.

Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96.

PREDICTING OUTCOME AFTER HEPATIC RESECTION

Adam R, Dennis A. Wicherts, Robbert J. de Haas, Oriana Ciacio, Francis Lévi, Bernard Paule, Michel Ducreux, Daniel Azoulay, Henri Bismuth, and Denis Castaing. Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?  J Clin Oncol 2009; [Epub ahead of print]

Fong, Y, Fortner, J, Sun, RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309.

Gold JS, Are C, Kornprat P, Jarnagin WR, Gönen M, Fong Y, DeMatteo RP, Blumgart LH, D'Angelica M. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008 Jan;247(1):109-17.

Kattan MW, Gönen M, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser M, Blumgart LH, Fong Y. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008 Feb;247(2):282-7.

Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, Neugut AI. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007 Dec 17;97(12):1606-12.

PREOPERATIVE CHEMOTHERAPY

Adam, R, Delvart, V, Pascal, G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644.

Adam, R, Aloia, T, Levi, F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25:4593.

Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D, Castaing D. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008 Apr 1;26(10):1635-41.

Alberts, SR, Horvath, WL, Sternfeld, WC, et al. Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. J Clin Oncol 2005; 23:9243.

Barone, C, Nuzzo, G, Cassano, A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97:1035.

Benoist, S, Brouquet, A, Penna, C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006; 24:3939.

Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20;26(33):5344-51.

Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008 Apr 10;26(11):1830-5.

Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010 Nov;17(11):2870-6. Epub 2010 Jun 22.

Klinger, M, Kandutsch, S, Hacker, S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: Effect of bevacizumab (abstract). Proc ASCO 2008 [4082].

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009 May;35(5):515-20.

Leonard, GD, Brenner, B, Kemeny, NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23:2038.

Masi, G, Cupini, S, Marcucci, L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13:58.

Meric, F, Patt, YZ, Curley, SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490.

Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007 Sep;43(14):2037-45

Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, Martin RC. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009 Jan;16(1):35-41.

Tamandl D, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol. 2009 Feb 20. [Epub ahead of print]

Zorzi D et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases. 2009 GI Cancers Symposium;Abstract 295.

PORTA HEPATIS NODES

Adam R et al. Is Hepatic Resection Justified After Chemotherapy in Patients With Colorectal Liver Metastases and Lymph Node Involvement? J Clin Oncol 2008;26(22):3672-80.

Bennett JJ, Schmidt CR, Klimstra DS, Grobmyer SR, Ishill NM, D'Angelica M, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol. 2008 Apr;15(4):1130-6.

Jaeck et al. Significance of Hepatic Pedicle Lymph Node Involvement in Patients with Colorectal Liver Metastases: A Prospective Study. Ann Surg Oncol 2002;9(5):430-8.

PORTAL VEIN EMBOLIZATION

Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008 Jan;247(1):49-57.  (See comment in: Ann Surg. 2008 Sep;248(3):499-500; author reply 500.).

Are C, Iacovitti S, Prete F, Crafa FM. Feasibility of laparoscopic portal vein ligation prior to major hepatectomy. HPB (Oxford). 2008;10(4):229-33.

Capussotti L, Muratore A, Baracchi F, Lelong B, Ferrero A, Regge D, Delpero JR. Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg. 2008 Oct;143(10):978-82; discussion 982.

Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, Sofocleous CT, D'Angelica M, Getrajdman GI, DeMatteo R, Kemeny NE, Fong Y. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008 Mar;247(3):451-5.

Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol. 2009 May;16(5):1202-7.

Wicherts DA, de Haas RJ, Andreani P, Sotirov D, Salloum C, Castaing D, Adam R, Azoulay D. Impact of Portal Vein Embolization on Long-Term Survival of Patients with Primarily Unresectable Colorectal Liver Metastases. Br J Surg. 2010 Feb;97(2):240-50.

Zorzi, D, Chun, YS, Madoff, DC, et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008; 15:2765.

RADIOFREQUENCY ABLATION

Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006 May;141(5):460-6; discussion 466-7. 

Rasmussen F. Radiofrequency ablation of liver metastases improves the survival rate of patients with metastatic colorectal disease. Acta Radiol. 2007 Apr;48(3):250-1. (See comment on: Acta Radiol. 2007 Apr;48(3):253-8.)

Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going? J Clin Oncol. 2005 Mar 1;23(7):1342-4. Epub 2005 Jan 31.

White RR, Avital I, Sofocleous CT, Brown KT, Brody LA, Covey A, Getrajdman GI, Jarnagin WR, Dematteo RP, Fong Y, Blumgart LH, D'Angelica M. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg. 2007 Mar;11(3):256-63. 

RADIOLOGIC DISEASE ASSESSMENT

Akhurst, T, Kates, TJ, Mazumdar, M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23:8713.

Cantwell CP, Setty BN, Holalkere N, Sahani DV, Fischman AJ, Blake MA. Liver lesion detection and characterization in patients with colorectal cancer: A comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 2008;32(5):738-44.

Dello SA, van Dam RM, Slangen JJ, van de Poll MC, Bemelmans MH, Greve JW, Beets-Tan RG, Wigmore SJ, Dejong CH. Liver volumetry plug and play: do it yourself with ImageJ. World J Surg. 2007 Nov;31(11):2215-21.

Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases.  Arch Surg. 2010 Apr;145(4):340-5; discussion 345.

Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227.

Koh DM, Brown G, Meer Z, Norman AR, Husband JE. Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AJR Am J Roentgenol. 2007 Feb;188(2):W154-61.

Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ. The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.  Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1323-9.

Lordan JT, Stenson KM, Karanjia ND. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg Engl. 2011 Apr;93(3):246-9.

Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, Wettergren A, Rasmussen A, Hillingsoe J, Kirkegaard P, Thomsen C. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 2007 May;48(4):369-78.

Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007 May;48(5):771-5.

Schwartz L, Brody L, Brown K, Covey A, Tuorto S, Mazumdar M, Riedel E, Jarnagin W, Getrajdman G, Fong Y. Prospective, blinded comparison of helical CT and CT arterial portography in the assessment of hepatic metastasis from colorectal carcinoma. World J Surg. 2006 Oct;30(10):1892-9; discussion 1900-1.

Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK, Hawkins WG, Siegel BA, Delbeke D, Pinson CW, Strasberg SM. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg. 2008 May;206(5):857-68; discussion 868-9.

Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007 Sep;11(9):1112-9.

Wiering, B, Krabbe, PF, Jager, GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104:2658.

Wiering, B, Oyen, W, Van der Sijp, J, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: a randomized study (abstract). Proc ASCO 2008 [4004]

RESECTABILITY CRITERIA

Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Cancer. 2011 Mar 28. doi: 10.1002/cncr.26036. [Epub ahead of print].

de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008 Oct;248(4):626-37.

Pawlik, TM, Schulick, RD, Choti, MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13:51.

Pawlik, TM, Abdalla, EK, Ellis, LM, et al. Debunking dogma: Surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 2006; 10:240.

Shimada H, Tanaka K, Masui H, Nagano Y, Matsuo K, Kijima M, Ichikawa Y, Ike H, Ooki S, Togo S. Results of surgical treatment for multiple (> or =5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg. 2004 Apr;389(2):114-21.

Welsh, FK, Tilney, HS, Tekkis, PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96:1037.

REPEAT LIVER RESECTIONS

Nordlinger, B, Vaillant, JC, Guiguet, M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491.

Pessaux, P, Lermite, E, Brehant, O, et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93:1.

Petrowsky, H, Gonen, M, Jarnagin, W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863.

Wicherts DA; Miller R; de Haas RJ; Bitsakou G; Vibert E; Veilhan LA; Azoulay D; Bismuth H; Castaing D; Adam R. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008 Dec;248(6):994-1005.

SURGICAL MARGINS

de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008 Oct;248(4):626-37.

Pawlik, TM, Scoggins, CR, Zorzi, D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715.

Welsh FK, Tekkis PP, O'Rourke T, John TG, Rees M. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol. 2008 Jul;17(1):3-13.

SURGICAL MORBIDITY AND MORTALITY

Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10;29(8):1083-90. Epub 2011 Jan 24.

Cummings, LC, Payes, JD, Cooper, GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109:718.

Gold JS, Are C, Kornprat P, Jarnagin WR, Gönen M, Fong Y, DeMatteo RP, Blumgart LH, D'Angelica M. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008 Jan;247(1):109-17.

Ito H, Are C, Gonen M, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008 Jun;247(6):994-1002.

Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009 Mar;249(3):420-5.

Rees, M, Tekkis, PP, Welsh, FK, et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients. Ann Surg 2008; 247:125.

Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer. 2009 Feb 15;115(4):752-9.

Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, Martin RC. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009 Jan;16(1):35-41.

Tomlinson, JS, Jarnagin, WR, DeMatteo, RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575.

Vauthey, JN, Pawlik, TM, Ribero, D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.

SYNCHRONOUS COLORECTAL LIVER METASTASES

de Santibanes, E, Lassalle, FB, McCormack, L, et al. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg 2002; 195:196.

Lyass, S, Zamir, G, Matot, I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001; 78:17.

Martin, R, Paty, P, Fong, Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197:233.

Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007 Aug;205(2):231-8.

Minagawa, M, Yamamoto, J, Miwa, S, et al. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg 2006; 141:1006.

Reddy, SK, Pawlik, TM, Zorzi, D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14:3481.

TYPES OF COLON CANCER SURGERY

Guzzetti E, Pulitanò C, Catena M, Arru M, Ratti F, Finazzi R, Aldrighetti L, Ferla G. Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis. J Surg Oncol. 2008 May 1;97(6):503-7.  (Also see comment in: J Surg Oncol. 2008 May 1;97(6):496.)

Hawkins WG, DeMatteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, Gonen M, Blumgart LH. Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg. 2005 Mar;200(3):345-52.

Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, Curley SA, Mentha G, Capussotti L, Vauthey JN. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg. 2006 Jan;10(1):86-94.

Copyright © 2008-2009 Research To Practice. All Rights Reserved.